Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- refractory or recurrent peptic ulcer disease
- diarrhea
Outros fatores diagnósticos
- epigastric abdominal pain
- gastroesophageal reflux disease
- steatorrhea
- gastrointestinal bleed
- bone pain
Fatores de risco
- multiple endocrine neoplasia type 1 (MEN1)
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- fasting serum gastrin
- gastric pH
Investigações a serem consideradas
- secretin stimulation test
- calcium infusion test
- glucagon test
- abdominal CT scan
- abdominal MRI scan
- somatostatin receptor scintigraphy (SRS)
- gallium(Ga)-68 DOTATATE PET
- endoscopic ultrasound (EUS)
- esophagogastroduodenoscopy (EGD)
- chest CT
- genetic testing for multiple endocrine neoplasia type 1 (MEN1)
Algoritmo de tratamento
localized disease: sporadic
localized disease: MEN1
metastatic disease: predominantly hepatic
metastatic disease: extrahepatic
Colaboradores
Autores
Joseph R. Pisegna, MD
Professor of Medicine
Chief
Division of Gastroenterology, Hepatology, and Parenteral Nutrition
David Geffen School of Medicine at University of California
VA Greater Los Angeles Healthcare System
Department of Veterans Affairs
Los Angeles
CA
Declarações
JRP is an author of a number of references cited in this topic. JRP has received a grant from Takeda Pharmaceuticals and is a speaker for Phathom Pharmaceuticals and AbbVie.
Agradecimentos
Dr Joseph R. Pisegna would like to gratefully acknowledge Dr Deepinder Goyal, Dr Jihane Benhammou, Dr David Oh, and Dr Hank Wang, previous contributors to this topic.
Declarações
DG, JB, DO, and HW declare that they have no competing interests.
Revisores
Peter Draganov, MD
Associate Professor of Medicine Division
Gastroenterology, Hepatology and Nutrition
University of Florida
Gainesville
FL
Declarações
PD declares that he has no competing interests.
Petros Perros, BSc, MBBS, MD, FRCP
Consultant Endocrinologist
Freeman Hospital
Newcastle-Upon-Tyne Hospitals Trust
UK
Declarações
PP declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referências
Principais artigos
Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153-71.Texto completo Resumo
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors [internet publication].Texto completo
Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77.Texto completo Resumo
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jul;31(7):844-60.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Atrophic gastritis
- Peptic ulcer disease from Helicobacter pylori infection
- Idiopathic gastric hypersecretion
Mais Diagnósticos diferenciaisGuidelines
- NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors
- Clinical practice update on management of subepithelial lesions encountered during routine endoscopy: expert review
Mais GuidelinesPatient information
Pancreatic cancer
Peptic ulcers
More Patient information
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer